Clinical trial · Observational
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Autoimmune encephalitis is brain inflammation caused by the immune system mistakenly reacting against proteins in the brain. The commonest form is called NMDAR-antibody encephalitis (N-methyl-D-aspartate receptor antibody encephalitis), a rare condition which mainly affects children and young people and causes difficulties in memory, thinking and mental health which can have significant long-term impacts on education, employment and quality of life. In this project we will use advanced magnetic resonance imaging (MRI) to measure changes in the structure, function and chemistry of the brains of children and young people who are in early recovery from NMDAR-antibody encephalitis and other forms of immune-mediated encephalitis. We will investigate if MRI measurements in patients differ from those in healthy people, and if they can help predict patient outcome one year later, assessed by tests of memory, thinking, mental health and functioning in daily life.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | — | UNRESOLVED | — |
| Autoimmune Encephalitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not applicable - non-interventional study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- NMDAR-antibody encephalitis
- description
- Children and young people (ages 8-24 years) with a diagnosis of NMDAR-antibody encephalitis.
- interventionNames
- Other: Not applicable - non-interventional study
- label
- Antibody-negative autoimmune encephalitis
- description
- Children and young people (ages 8-24 years) with a diagnosis of autoantibody-negative but probable autoimmune encephalitis or definite autoimmune limbic encephalitis.
- interventionNames
- Other: Not applicable - non-interventional study
- label
- Healthy control
- description
- Healthy children and young people (ages 8-24 years).
- interventionNames
- Other: Not applicable - non-interventional study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
- Maximum age
- 24 Years
Show eligibility criteria text
INCLUSION CRITERIA: NMDAR-antibody encephalitis group: 1. Age 8-24 years at study enrollment. 2. Disease onset in the last 12 months before study enrollment. 3. Meets consensus diagnostic criteria (Graus et al., 2016) for either probable anti-NMDAR encephalitis OR definite anti-NMDAR encephalitis. Antibody-negative autoimmune encephalitis group: 1. Age 8-24 years at study enrollment. 2. Disease onset in the last 12 months before study enrollment. 3. Meets consensus diagnostic criteria (Graus et al., 2016) for either autoantibody-negative but probable autoimmune encephalitis OR definite autoimmune limbic encephalitis. Healthy control group: 1\. Age 8-24 years at study enrollment. EXCLUSION CRITERIA: All participants: 1\. Any clear contra-indication for an MRI scan. In particular this would be due to the presence of any implanted devices or metal from previous surgery or accident. Healthy control group: 1\. A known neurological or neurodevelopmental disorder. NMDAR-antibody encephalitis and antibody-negative autoimmune encephalitis groups: 1. Alternative more likely cause of neurological symptoms than autoimmune encephalitis, i.e. reasonable exclusion of other diagnoses as per consensus criteria (Graus et al., 2016). 2. Severe movement disorder/uncontrolled epilepsy/dysautonomia. 3. Previous infective encephalitis with major destructive brain lesions.
References
Publications (1)
- BACKGROUNDGraus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Hoftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Pruss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20. PMID 26906964